Re:YC and Ginkgo Bioworks announce new partnership for synth...
by nemanja-mit on Monday September 16, 2019 @05:39PM
(#20988837)
Surprisingly, bio is pretty similar to software capital-wise, at least initially and the standard YC deal works well. Jared and Jorge wrote good pieces around this recently -
Re:YC and Ginkgo Bioworks announce new partnership for synth...
by kayhi on Monday September 16, 2019 @06:41PM
(#20989280)
I would see this more of a reflection of spend matching the access to capital not that bio is similar to software. The difference between moving atoms and bits is significant.
https://blog.ycombinator.com/how-biotech-startup-funding-wil...
https://techcrunch.com/2019/08/09/biotech-researchers-ventur...
Case in point - Asher Bio from the most recent YC batch went from zero to a working molecule & in-vivo data in ~3 months on the standard deal - https://techcrunch.com/2019/08/20/here-are-the-82-startups-t...